DPYD, down-regulated by the potentially chemopreventive agent luteolin, interacts with STAT3 in pancreatic cancer.
Aged
Animals
Apoptosis
Carcinoma, Pancreatic Ductal
/ drug therapy
Cell Proliferation
Cricetinae
Dihydrouracil Dehydrogenase (NADP)
/ antagonists & inhibitors
Female
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Luteolin
/ pharmacology
Male
Mice
Pancreatic Neoplasms
/ drug therapy
Prognosis
STAT3 Transcription Factor
/ genetics
Survival Rate
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Journal
Carcinogenesis
ISSN: 1460-2180
Titre abrégé: Carcinogenesis
Pays: England
ID NLM: 8008055
Informations de publication
Date de publication:
16 07 2021
16 07 2021
Historique:
received:
16
03
2020
revised:
30
01
2021
accepted:
25
02
2021
pubmed:
1
3
2021
medline:
23
11
2021
entrez:
28
2
2021
Statut:
ppublish
Résumé
The 5-year survival rate of pancreatic ductal carcinoma (PDAC) patients is <10% despite progress in clinical medicine. Strategies to prevent the development of PDAC are urgently required. The flavonoids Luteolin (Lut) and hesperetin (Hes) may be cancer-chemopreventive, but effects on pancreatic carcinogenesis in vivo have not been studied. Here, the chemopreventive effects of Lut and Hes on pancreatic carcinogenesis are assessed in the BOP-induced hamster PDAC model. Lut but not Hes suppressed proliferation of pancreatic intraepithelial neoplasia (PanIN) and reduced the incidence and multiplicity of PDAC in this model. Lut also inhibited the proliferation of hamster and human pancreatic cancer cells in vitro. Multi-blot and microarray assays revealed decreased phosphorylated STAT3 (pSTAT3) and dihydropyrimidine dehydrogenase (DPYD) on Lut exposure. To explore the relationship between DPYD and STAT3 activity, the former was silenced by RNAi or overexpressed using expression vectors, and the latter was inactivated by small molecule inhibitors or stimulated by IL6 in human PDAC cells. DPYD knock-down decreased, and overexpression increased, pSTAT3 and cell proliferation. DPYD expression was decreased by inactivation of STAT3 and increased by its activation. The frequency of pSTAT3-positive cells and DPYD expression was significantly correlated and was decreased in parallel by Lut in the hamster PDAC model. Finally, immunohistochemical analysis in 73 cases of human PDAC demonstrated that DPYD expression was positively correlated with the Ki-67 labeling index, and high expression was associated with poor prognosis. These results indicate that Lut is a promising chemopreventive agent for PDAC, targeting a novel STAT3-DPYD pathway.
Identifiants
pubmed: 33640964
pii: 6153425
doi: 10.1093/carcin/bgab017
pmc: PMC8283735
doi:
Substances chimiques
STAT3 Transcription Factor
0
STAT3 protein, human
0
Dihydrouracil Dehydrogenase (NADP)
EC 1.3.1.2
Luteolin
KUX1ZNC9J2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
940-950Subventions
Organisme : Ono Pharmaceutical
Organisme : Japan Society for the Promotion of Science
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press.
Références
Cancer Chemother Pharmacol. 1994;34(2):147-52
pubmed: 8194165
Metabolomics. 2012 Apr 1;8(2):201-210
pubmed: 22754424
Pancreas. 2015 Jan;44(1):144-51
pubmed: 25237909
FASEB J. 2019 Feb;33(2):1972-1988
pubmed: 30226808
Int J Cancer. 2010 Oct 15;127(8):1913-22
pubmed: 20104526
Carcinogenesis. 2015 Dec;36(12):1539-49
pubmed: 26494227
Cancer Sci. 2020 Apr;111(4):1165-1179
pubmed: 31994822
Int J Clin Oncol. 2007 Apr;12(2):111-9
pubmed: 17443278
Int J Clin Oncol. 2010 Feb;15(1):39-45
pubmed: 20072795
IUBMB Life. 2015 Mar;67(3):191-201
pubmed: 25873402
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
Asian Pac J Cancer Prev. 2014;15(14):5501-8
pubmed: 25081655
Oncol Lett. 2017 Aug;14(2):1505-1511
pubmed: 28789372
Br J Cancer. 2018 Apr;118(7):947-954
pubmed: 29515256
Cancer Res. 2019 Jan 15;79(2):372-386
pubmed: 30401713
Cancer Res. 1997 Jan 15;57(2):246-52
pubmed: 9000563
Mol Med Rep. 2018 Mar;17(3):3681-3689
pubmed: 29286098
J Exp Med. 2017 Mar 6;214(3):579-596
pubmed: 28232471
Int J Biochem Cell Biol. 2016 Sep;78:268-278
pubmed: 27458056
Carcinogenesis. 1997 May;18(5):957-65
pubmed: 9163681
Phytomedicine. 2019 May;58:152762
pubmed: 31005717
Sci Rep. 2015 Dec 03;5:17663
pubmed: 26631279
Cancer Res. 2013 Dec 15;73(24):7313-23
pubmed: 24165159
Carcinogenesis. 1997 Apr;18(4):761-9
pubmed: 9111212
Jpn J Cancer Res. 1987 Jul;78(7):748-55
pubmed: 3114201
Digestion. 2018;97(4):275-287
pubmed: 29587290
Cell Death Dis. 2018 Jan 22;9(2):69
pubmed: 29358721
Cancer Prev Res (Phila). 2014 Jan;7(1):65-73
pubmed: 24403290
Asia Pac J Clin Nutr. 2015;24(3):456-63
pubmed: 26420187
Pancreas. 2011 Nov;40(8):1234-40
pubmed: 21989024
Sci Rep. 2019 Mar 28;9(1):5303
pubmed: 30923340
Nutrients. 2017 Sep 29;9(10):
pubmed: 28961176
Cancer Res. 1976 Jul;36(7 PT 2):2699-702
pubmed: 1277177
Oncotarget. 2015 Dec 15;6(40):42963-75
pubmed: 26556864
Chem Biol. 2006 Nov;13(11):1235-42
pubmed: 17114005
Int J Mol Sci. 2018 Feb 02;19(2):
pubmed: 29393891
Onco Targets Ther. 2015 Oct 19;8:2989-3001
pubmed: 26527884
Cancer Res. 2011 Jul 15;71(14):5020-9
pubmed: 21586612
J Med Food. 2011 Apr;14(4):325-33
pubmed: 21443429
Carcinogenesis. 2020 Aug 12;41(8):1145-1157
pubmed: 31805186
Sci Rep. 2017 May 11;7(1):1787
pubmed: 28496202
Nature. 2019 May;569(7754):131-135
pubmed: 30996350
Cancer. 2019 Nov 15;125(22):3927-3935
pubmed: 31381149
Mol Cancer Ther. 2014 Mar;13(3):742-51
pubmed: 24401318
Cancer Res. 2016 Nov 1;76(21):6362-6373
pubmed: 27578004
Oncol Rep. 2012 Oct;28(4):1353-61
pubmed: 22825765